Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
Stock Summary
Top Correlated Resources
LIFE.ME
Top 10 Correlated ETFs
LIFE.ME
Top 10 Correlated Stocks
LIFE.ME
Financial details
Company Rating
-
Market Cap
1.36B
Income
-
Revenue
-
Book val./share
16.37
Cash/share
3.59
Dividend
-
Dividend %
-
Employees
119
Optionable
No
Shortable
Yes
Earnings
-
P/E
-133.12
Forward P/E
-
PEG
-
P/S
8.36
P/B
0.12
P/C
1.25
P/FCF
-7.37
Quick Ratio
0.01
Current Ratio
0.27
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
32.91%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-23.98%
Revenue last 5Y
-9.54%
Revenue Q/Q
44.23%
EPS Q/Q
-171.55%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-0.01%
Gross Margin
55%
Oper. Margin
-53%
Profit Margin
-6%
Payout
-
Shs Outstand
301.01M
Shs Float
112.77M
-
-
-
-
Target Price
-
52W Range
2.645-7.0
52W High
-35.64%
52W Low
+125.25%
RSI
33
Rel Volume
-
Avg Volume
-
Volume
27.53M
Perf Week
7.52%
Perf Month
1.46%
Perf Quarter
5.5%
Perf Half Y
-3.53%
-
-
-
-
Beta
0.175213
-
-
Volatility
0.38%, 0.54%
Prev Close
30.39%
Price
4.505
Change
32.5%
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 2.62 | 0.94 | 0.39 | 1.23 | 1.46 | |
| Net income per share | -9.13 | 0.2 | -2.3 | -1.74 | -2.32 | |
| Operating cash flow per share | -0.5 | 0 | 0 | -0.77 | -0.21 | |
| Free cash flow per share | -0.59 | -0.05 | -0.32 | -0.81 | -0.21 | |
| Cash per share | 1.37 | 0.05 | 0.25 | 0.03 | 0.05 | |
| Book value per share | 6.37 | 16.22 | 13.92 | 3.37 | 1.15 | |
| Tangible book value per share | 2.59 | 14.86 | 12.56 | 1.98 | -0.18 | |
| Share holders equity per share | 6.37 | 16.22 | 13.92 | 3.37 | 1.15 | |
| Interest debt per share | 0.86 | 0.1 | 0.64 | 2.17 | 2.47 | |
| Market cap | 3.31B | 1.93B | 2.42B | 2B | 1.43B | |
| Enterprise value | 3.22B | 1.95B | 2.52B | 2.61B | 2.12B | |
| P/E ratio | -1.31 | 32.29 | -3.5 | -3.81 | -2.05 | |
| Price to sales ratio | 4.58 | 6.85 | 20.64 | 5.39 | 3.26 | |
| POCF ratio | -24.1 | 0 | 0 | -8.6 | -22.81 | |
| PFCF ratio | -20.49 | -124.63 | -25.09 | -8.26 | -22.7 | |
| P/B Ratio | 1.88 | 0.4 | 0.58 | 1.97 | 4.14 | |
| PTB ratio | 1.88 | 0.4 | 0.58 | 1.97 | 4.14 | |
| EV to sales | 4.45 | 6.93 | 21.49 | 7.04 | 4.84 | |
| Enterprise value over EBITDA | -1.27 | 256.47 | -3.46 | -5.77 | -3.19 | |
| EV to operating cash flow | -23.42 | 0 | 0 | -11.23 | -33.86 | |
| EV to free cash flow | -19.9 | -126.11 | -26.11 | -10.79 | -33.71 | |
| Earnings yield | -0.76 | 0.03 | -0.29 | -0.26 | -0.49 | |
| Free cash flow yield | -0.05 | -0.01 | -0.04 | -0.12 | -0.04 | |
| Debt to equity | 0.03 | 0 | 0.04 | 0.01 | 0.25 | |
| Debt to assets | 0.47 | 0.25 | 0.29 | 0.51 | 0.76 | |
| Net debt to EBITDA | 0.04 | 3.02 | -0.14 | -1.35 | -1.04 | |
| Current ratio | 0.97 | 0.38 | 0.27 | 0.45 | 0.21 | |
| Interest coverage | -211.43 | 11.49 | -8.66 | -1.4 | -17.69 | |
| Income quality | 0.05 | 0 | 0 | 0.44 | 0.09 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.42 | 0.06 | 0.05 | 0.06 | 0.08 | |
| Research and developement to revenue | 0.37 | 0 | 0 | 0.13 | 0.12 | |
| Intangibles to total assets | 0.32 | 0.06 | 0.07 | 0.2 | 0.28 | |
| Capex to operating cash flow | 0.18 | 0 | 0 | 0.04 | 0 | |
| Capex to revenue | -0.03 | 0 | 0 | -0.03 | 0 | |
| Capex to depreciation | -0.48 | 0 | 0 | -0.22 | -0.01 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 36.18 | 8.51 | 26.85 | 11.5 | 7.73 | |
| ROIC | -0.43 | 0.01 | -0.06 | -0.04 | -1.49 | |
| Return on tangible assets | -1.1 | 0.01 | -0.13 | -0.32 | -0.68 | |
| Graham Net | -4 | -4.89 | -5.1 | -3.3 | -3.48 | |
| Working capital | -30.17M | -810.91M | -1.09B | -559.73M | -787.05M | |
| Tangible asset value | 715.19M | 4.47B | 3.78B | 596.1M | -55.18M | |
| Net current asset value | -476.9M | -1.12B | -1.29B | -572.92M | -873.9M | |
| Invested capital | 0.13 | 0 | 0.04 | 0.61 | 2.05 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 230.78M | 347.49M | 340.8M | 177.77M | 159.53M | |
| Average inventory | 137.81M | 169.7M | 111.46M | 69.56M | 52.87M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 250.07 | 753.34 | 1.54K | 306.44 | 185.98 | |
| Days of inventory on hand | 181.58 | 393.03 | 469.13 | 119.91 | 47.63 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.46 | 0.48 | 0.24 | 1.19 | 1.96 | |
| Inventory turnover | 2.01 | 0.93 | 0.78 | 3.04 | 7.66 | |
| ROE | -1.43 | 0.01 | -0.17 | -0.52 | -2.02 | |
| Capex per share | -0.09 | 0 | 0 | -0.03 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2014-03-31 for Q1
| Metric | History | 2014-03-31 |
|---|---|---|
| Revenue per share | 0.32 | |
| Net income per share | 0.09 | |
| Operating cash flow per share | -1.68 | |
| Free cash flow per share | -1.85 | |
| Cash per share | 3.59 | |
| Book value per share | 16.37 | |
| Tangible book value per share | 16.37 | |
| Share holders equity per share | 16.37 | |
| Interest debt per share | 0 | |
| Market cap | 1.87B | |
| Enterprise value | 1.48B | |
| P/E ratio | 44.07 | |
| Price to sales ratio | 47.17 | |
| POCF ratio | -8.91 | |
| PFCF ratio | -8.12 | |
| P/B Ratio | 0.92 | |
| PTB ratio | 0.92 | |
| EV to sales | 37.18 | |
| Enterprise value over EBITDA | 64 | |
| EV to operating cash flow | -7.02 | |
| EV to free cash flow | -6.4 | |
| Earnings yield | 0.01 | |
| Free cash flow yield | -0.12 | |
| Debt to equity | 0 | |
| Debt to assets | 0.28 | |
| Net debt to EBITDA | -17.2 | |
| Current ratio | 1.72 | |
| Interest coverage | 0 | |
| Income quality | -19.79 | |
| Dividend Yield | 0 | |
| Payout ratio | 0 | |
| Sales general and administrative to revenue | 0.56 | |
| Research and developement to revenue | 0 | |
| Intangibles to total assets | 0 | |
| Capex to operating cash flow | 0.1 | |
| Capex to revenue | -0.51 | |
| Capex to depreciation | -2.24 | |
| Stock based compensation to revenue | 0 | |
| Graham number | 5.6 | |
| ROIC | -0.01 | |
| Return on tangible assets | 0 | |
| Graham Net | -2.29 | |
| Working capital | 567.46M | |
| Tangible asset value | 0 | |
| Net current asset value | 554.94M | |
| Invested capital | 0 | |
| Average receivables | 0 | |
| Average payables | 0 | |
| Average inventory | 167M | |
| Days sales outstanding | 0 | |
| Days payables outstanding | 0 | |
| Days of inventory on hand | 1.2K | |
| Receivables turnover | 0 | |
| Payables turnover | 0 | |
| Inventory turnover | 0.07 | |
| ROE | 0.01 | |
| Capex per share | -0.16 |
Frequently Asked Questions
What is Farmsintez PAO stock symbol ?
Farmsintez PAO is a RU stock and trading under the symbol LIFE.ME
What is Farmsintez PAO stock quote today ?
Farmsintez PAO stock price is $4.505 today.
Is Farmsintez PAO stock public?
Yes, Farmsintez PAO is a publicly traded company.
Company Profile
- Market Capitalization 1.36B
- Employee 119
- Headquarters LENINGRADSKAYA OBLAST,RU
- IPO Date 2010-11-24
-
Website
https://www.pharmsynthez.com 
Public Joint-Stock Company 'Pharmsynthez', a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia and CIS countries. The company offers officinal medicines, including Neovir, Segidrin, Fenasid, and Penkrofton that are used in oncology, gynecology, treatment of immune deficiencies, and tuberculosis. Public Joint-Stock Company 'Pharmsynthez' has partnership with HiFiBiO Therapeutics Inks for the clinical development and commercialization of its SARS-CoV-2 neutralizing antibody in Russia. Public Joint-Stock Company 'Pharmsynthez' was founded in 1996 and is based in St. Petersburg, Russia.
